C. DIFFICILE

Assessing Vancomycin and Metronidazole Susceptibility for CDI

May 23, 2022

Video

A team of investigators studied Clostridioides difficile infection (CDI) isolates to gauge resistance in the 2 antibiotics.

Investigational Therapy SER-109 Prevents Recurrent C Difficile Infection

May 23, 2022

Article

Seres Therapeutics shared phase 3 trial results demonstrating their investigational microbiome-based therapeutic, SER-109, prevented recurrent C difficile infection (rCDI) in 88% of recipients.

Managing CDI in the Ambulatory Setting

May 22, 2022

Video

Investigators sought information on how the infection is treated in outpatient clinics

Examining Clostridioides difficile Incidence and Clinical Impact Across the US

May 20, 2022

Video

In a poster presented at MAD-ID 2022, Glenn S. Tillotson, PhD, FIDSA, FCCP, shares data from the Premier Healthcare Database on more than 100,000 patients with C diff.

Role of the Microbiome in Preventing Recurrent C difficile Infection

May 20, 2022

Video

Colleen R. Kelly, MD, FACG, speaks at MAD-ID 2022 on alternatives to antibiotics for C diff infection, including the use of probiotics and fecal microbiota transplantation.

A Unique Device That Aids in Fecal Microbiota Transplant

May 16, 2022

Video

Tend, a startup company, has developed its Gut Microbiome Collect and Prep (CAP) to enable a standardized method for stool (microbiome) encapsulation for the procedure.

In C Diff, New Attention Being Paid to the Role of the Virome

May 11, 2022

Article

Most of the discussion around fecal microbiota transplantation has focused on bacterial communities, but new advances have shed more light on the role of the virome.

C Difficile May Spread Zoonotically Between Pigs and Humans

May 04, 2022

Article

Antibiotic-resistant strains of the dangerous superbug C difficile have been identified in pigs and humans, suggesting zoonotic transmission is possible.

Better Sampling to Reduce C Difficile Misdiagnosis

May 03, 2022

Article

Improving stool sample collecting and testing reduced C difficile underdiagnosis.

Rifaximin Effective in Majority of Patients Recurrent CDI Who Do Not Respond to Metronidazole

May 01, 2022

Article

About 65% of patients with metronidazole-resistant recurrent C difficile infection benefitted from taking rifaximin.

Latest News

“Doing Quality Work, With Vigor”: Designing the Next Generation Pneumococcal Vaccine

CDC Identifies Adenovirus Infections in 45% of Acute Hepatitis Cases in Children

CDC on the Meningococcal Disease Outbreak: Gay and Bisexual Men Should Get Vaccinated if Living or Traveling to Florida

Combination bNAbs Therapy Could Eventually Replace Daily ART

View More News